viral vaccines

Summary

Summary: Suspensions of attenuated or killed viruses administered for the prevention or treatment of infectious viral disease.

Top Publications

  1. doi Virology, epidemiology, pathogenesis, and control of enterovirus 71
    Tom Solomon
    Brain Infections Group, Institute of Infection and Global Health, University of Liverpool, Liverpool, UK
    Lancet Infect Dis 10:778-90. 2010
  2. doi Identification and characterization of a cross-neutralization epitope of Enterovirus 71
    Chia Chyi Liu
    Vaccine R and D Center, National Health Research Institutes, Zhunan Town, Miaoli County 350, Taiwan
    Vaccine 29:4362-72. 2011
  3. ncbi Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus
    C N Wu
    Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan, ROC
    Vaccine 20:895-904. 2001
  4. doi Development of enterovirus 71 vaccines
    Min Shi Lee
    Vaccine Research and Development Center, National Health Research Institutes, Taiwan
    Expert Rev Vaccines 9:149-56. 2010
  5. ncbi Hemorrhagic fever viruses as biological weapons: medical and public health management
    Luciana Borio
    Johns Hopkins Center for Civilian Biodefense Strategies, Johns Hopkins Schools of Medicine and Public Health, 111 Market Pl, Suite 830, Baltimore, MD 21202, USA
    JAMA 287:2391-405. 2002
  6. doi Selection and characterization of vaccine strain for Enterovirus 71 vaccine development
    Jui Yuan Chang
    Vaccine R and D Center, National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan Township, Miaoli County 350, Taiwan
    Vaccine 30:703-11. 2012
  7. ncbi Neutralizing antibody provided protection against enterovirus type 71 lethal challenge in neonatal mice
    C K Yu
    Department of Microbiology and Immunology, College of Medicine, National Cheng Kung University, Tainan, Taiwan, ROC
    J Biomed Sci 7:523-8. 2000
  8. pmc Rift valley fever: recent insights into pathogenesis and prevention
    Hani Boshra
    Centro de Investigación en Sanidad Animal CISA INIA, Carretera de Valdeolmos El Casar s n, Valdeolmos, Madrid, Spain 28130
    J Virol 85:6098-105. 2011
  9. doi Formalin-inactivated vaccine provokes cross-protective immunity in a mouse model of human enterovirus 71 infection
    Emily Jane Bek
    Infectious Diseases and Immunology, The University of Sydney, Australia
    Vaccine 29:4829-38. 2011
  10. pmc Recombinant Rift Valley fever vaccines induce protective levels of antibody in baboons and resistance to lethal challenge in mice
    James F Papin
    International Laboratory of Molecular Biology for Tropical Disease Agents, School of Veterinary Medicine, University of California, Davis, CA 95616, USA
    Proc Natl Acad Sci U S A 108:14926-31. 2011

Research Grants

  1. PATHOGENIC CONVERSION OF ATTENUATED SIV VACCINES
    Earl Sawai; Fiscal Year: 2003
  2. Molecular Basis of Flavivirus Neurovirulence
    William Wold; Fiscal Year: 2007
  3. The Immunogenetics of Measles Immunity
    Gregory A Poland; Fiscal Year: 2010
  4. The Immunogenetics of Measles Immunity
    Gregory Poland; Fiscal Year: 2009
  5. IMMUNOGENETIC MECHANISMS OF VACCINE RESPONSE
    Gregory Poland; Fiscal Year: 2005
  6. CHILDHOOD VACCINES AND DENTAL CARIES IMMUNITY
    Daniel Smith; Fiscal Year: 2007
  7. Microcarrier / CEF / Media SYSTEM to make Viral Vaccines
    WILLIAM HILLEGAS; Fiscal Year: 2002
  8. Molecular Basis of Flavivirus Neurovirulence
    Ilya Frolov; Fiscal Year: 2003
  9. The Immunogenetics of Measles Immunity
    Gregory Poland; Fiscal Year: 2006
  10. HIV Vaccine Design and Development Team
    PAUL MADDON; Fiscal Year: 2001

Detail Information

Publications376 found, 100 shown here

  1. doi Virology, epidemiology, pathogenesis, and control of enterovirus 71
    Tom Solomon
    Brain Infections Group, Institute of Infection and Global Health, University of Liverpool, Liverpool, UK
    Lancet Infect Dis 10:778-90. 2010
    ..Vaccines being developed include inactivated whole-virus, live attenuated, subviral particle, and DNA vaccines...
  2. doi Identification and characterization of a cross-neutralization epitope of Enterovirus 71
    Chia Chyi Liu
    Vaccine R and D Center, National Health Research Institutes, Zhunan Town, Miaoli County 350, Taiwan
    Vaccine 29:4362-72. 2011
    ..Thus, VP2-28 could be used as the surrogate biomarker in the potency testing of candidate EV71 vaccines...
  3. ncbi Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus
    C N Wu
    Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan, ROC
    Vaccine 20:895-904. 2001
    ..Our data indicated that inactivated virus is the choice of vaccine preparation capable of fulfilling the demand for effective control, and that VP1 subunit vaccines remain promising vaccine strategies that require further refinement...
  4. doi Development of enterovirus 71 vaccines
    Min Shi Lee
    Vaccine Research and Development Center, National Health Research Institutes, Taiwan
    Expert Rev Vaccines 9:149-56. 2010
    ....
  5. ncbi Hemorrhagic fever viruses as biological weapons: medical and public health management
    Luciana Borio
    Johns Hopkins Center for Civilian Biodefense Strategies, Johns Hopkins Schools of Medicine and Public Health, 111 Market Pl, Suite 830, Baltimore, MD 21202, USA
    JAMA 287:2391-405. 2002
    ..To develop consensus-based recommendations for measures to be taken by medical and public health professionals if hemorrhagic fever viruses (HFVs) are used as biological weapons against a civilian population...
  6. doi Selection and characterization of vaccine strain for Enterovirus 71 vaccine development
    Jui Yuan Chang
    Vaccine R and D Center, National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan Township, Miaoli County 350, Taiwan
    Vaccine 30:703-11. 2012
    ..Therefore, these results provide valuable information for cell-based EV71 vaccine development...
  7. ncbi Neutralizing antibody provided protection against enterovirus type 71 lethal challenge in neonatal mice
    C K Yu
    Department of Microbiology and Immunology, College of Medicine, National Cheng Kung University, Tainan, Taiwan, ROC
    J Biomed Sci 7:523-8. 2000
    ..Pups from hyperimmune dams were resistant to EV71 challenge. Additionally, maternal immunization with a formalin-inactivated whole-virus vaccine prolonged the survival of pups after EV71 lethal challenge...
  8. pmc Rift valley fever: recent insights into pathogenesis and prevention
    Hani Boshra
    Centro de Investigación en Sanidad Animal CISA INIA, Carretera de Valdeolmos El Casar s n, Valdeolmos, Madrid, Spain 28130
    J Virol 85:6098-105. 2011
    ..Progress in understanding the epidemiology of Rift Valley fever has also enabled prediction of potential outbreaks well in advance, thus providing another tool to combat the physical and economic impact of this disease...
  9. doi Formalin-inactivated vaccine provokes cross-protective immunity in a mouse model of human enterovirus 71 infection
    Emily Jane Bek
    Infectious Diseases and Immunology, The University of Sydney, Australia
    Vaccine 29:4829-38. 2011
    ..Immunised mice developed a neutralising antibody response to both the immunising C4 strain and to the mouse-adapted strain. Mice born to immunised dams showed significantly less myositis and reduced viral loads in tissues...
  10. pmc Recombinant Rift Valley fever vaccines induce protective levels of antibody in baboons and resistance to lethal challenge in mice
    James F Papin
    International Laboratory of Molecular Biology for Tropical Disease Agents, School of Veterinary Medicine, University of California, Davis, CA 95616, USA
    Proc Natl Acad Sci U S A 108:14926-31. 2011
    ..Furthermore, both vaccines induced protective levels of antibody titers in vaccinated mice and baboons. Mice were protected from lethal RVFV challenge. Thus, we have developed two safe and efficacious recombinant vaccines for RVF...
  11. pmc The major determinant of attenuation in mice of the Candid1 vaccine for Argentine hemorrhagic fever is located in the G2 glycoprotein transmembrane domain
    Cesar G Albarino
    Centers for Disease Control and Prevention, MS G14, Atlanta, GA 30329, USA
    J Virol 85:10404-8. 2011
    ..This work provides insight into the molecular mechanisms of attenuation of the only arenavirus vaccine currently available...
  12. doi Effective induction of high-titer antibodies by viral vector vaccines
    Simon J Draper
    The Jenner Institute, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Headington, Oxford OX3 7DQ, UK
    Nat Med 14:819-21. 2008
    ..Antibodies induced against a blood-stage malaria antigen by this viral vector platform are highly effective against Plasmodium yoelii parasites in mice and against Plasmodium falciparum in vitro...
  13. ncbi Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity
    Dan H Barouch
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    J Immunol 172:6290-7. 2004
    ..Moreover, these studies suggest that using Ad vectors derived from immunologically distinct serotypes may be an effective and general strategy to overcome the suppressive effects of pre-existing anti-Ad immunity...
  14. doi Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge
    Yao Chi Chung
    Department of Chemical Engineering, National Tsing Hua University, Hsinchu 300, Taiwan
    Vaccine 26:1855-62. 2008
    ..These data collectively indicate the importance of the preservation of VLP structure and implicate the potential of VLP as a vaccine to prevent EV71 infection...
  15. pmc Chikungunya virus arthritis in adult wild-type mice
    Joy Gardner
    Queensland Institute of Medical Research, Australian Centre for International and Tropical Health, Brisbane, Australia
    J Virol 84:8021-32. 2010
    ..This new mouse model of chikungunya virus disease thus provides insights into pathogenesis and a simple and convenient system to test potential new interventions...
  16. ncbi High immunogenic enterovirus 71 strain and its production using serum-free microcarrier Vero cell culture
    Chia Chyi Liu
    Institute of Biotechnology, Department of Life Science, National Tsing Hua University, Hsinchu, Taiwan
    Vaccine 25:19-24. 2007
    ..Therefore, serum-free microcarrier culture is a valuable process for developing inactivated EV71 vaccines...
  17. pmc A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection
    Wataru Akahata
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, US National Institutes of Health, Bethesda, Maryland, USA
    Nat Med 16:334-8. 2010
    ..Immunization with alphavirus VLP vaccines represents a strategy to contain the spread of CHIKV and related pathogenic viruses in humans...
  18. doi Novel strategies and approaches to develop the next generation of vaccines against porcine reproductive and respiratory syndrome virus (PRRSV)
    Y W Huang
    Center for Molecular Medicine and Infectious Diseases, Department of Biomedical Sciences and Pathobiology, College of Veterinary Medicine, Virginia Polytechnic Institute and State University, Blacksburg, VA 24061 0913, USA
    Virus Res 154:141-9. 2010
    ....
  19. doi Immunoprotection elicited by an enterovirus type 71 experimental inactivated vaccine in mice and rhesus monkeys
    Chenghong Dong
    Institute of Medical Biology, Chinese Academy of Medicine Science, Kunming 650118, PR China
    Vaccine 29:6269-75. 2011
    ....
  20. doi Safety and immunogenicity of a novel human Enterovirus 71 (EV71) vaccine: a randomized, placebo-controlled, double-blind, Phase I clinical trial
    Yan Ping Li
    The Center for Disease Control and Prevention of the Guangxi Zhuang Autonomous Region, China
    Vaccine 30:3295-303. 2012
    ..6-15.3), and 27.4 (95% CI, 14.3-52.2) in the 100 U, 200 U, and 400 U vaccine groups, respectively; after two doses, the GMTs were 114.1 (95% CI, 44.5-292.4), 159.5 (95% CI, 49.3-515.3), and 509.0 (95% CI, 181.3-1429.1), respectively...
  21. doi Current strategies for subunit and genetic viral veterinary vaccine development
    Alejandro Brun
    Centro de Investigación en Sanidad Animal CISA INIA, Valdeolmos, 28130 Madrid, Spain
    Virus Res 157:1-12. 2011
    ..This paper reviews several antigen production and delivery strategies other than those based on the use of live viral vectors. Genetic and protein subunit vaccines as well as alternative production systems are considered in this review...
  22. pmc Filovirus vaccines
    Steven B Bradfute
    United States Army Medical Research Institute of Infectious Diseases, National Interagency Biodefense Campus Fort Detrick, Frederick, MD, USA
    Hum Vaccin 7:701-11. 2011
    ..Furthermore, the uses of rodent models in vaccine development, as well as correlates of immunity, are discussed...
  23. pmc Rescue of Newcastle disease virus from cloned cDNA: evidence that cleavability of the fusion protein is a major determinant for virulence
    B P Peeters
    Department of Avian Virology, Institute for Animal Science and Health, 8200 AB Lelystad, The Netherlands
    J Virol 73:5001-9. 1999
    ..These results demonstrate that genetically modified NDV can be recovered from cloned cDNA and confirm the supposition that cleavage of the F0 protein is a key determinant in virulence of NDV...
  24. doi The Xs and Y of immune responses to viral vaccines
    Sabra L Klein
    W Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
    Lancet Infect Dis 10:338-49. 2010
    ..clinical data illustrate that men and women differ in their innate, humoral, and cell-mediated responses to viral vaccines. Sex affects the frequency and severity of adverse effects of vaccination, including fever, pain, and ..
  25. pmc Progress in filovirus vaccine development: evaluating the potential for clinical use
    Darryl Falzarano
    Laboratory of Virology, Rocky Mountain Laboratories, Division of Intramural Research, National Institute of Allergy and Infectious Disease, National Institutes of Health, 903 South 4th Street, Hamilton, MT 59840, USA
    Expert Rev Vaccines 10:63-77. 2011
    ..These results demonstrate that achieving a vaccine that is protective against filoviruses is possible; the challenge now is to prove its safety and efficacy in order to obtain a vaccine that is ready for human use...
  26. pmc Protective cytotoxic T-cell responses induced by venezuelan equine encephalitis virus replicons expressing Ebola virus proteins
    Gene G Olinger
    United States Army Medical Research Institute of Infectious Diseases, Division of Virology, 1425 Porter Street, Frederick, MD 21702 5011, USA
    J Virol 79:14189-96. 2005
    ....
  27. doi Challenges for porcine reproductive and respiratory syndrome virus (PRRSV) vaccinology
    Tjeerd G Kimman
    Central Veterinary Institute of Wageningen UR CVI, P O Box 65, 8200 AB Lelystad, The Netherlands
    Vaccine 27:3704-18. 2009
    ....
  28. pmc Protection of European domestic pigs from virulent African isolates of African swine fever virus by experimental immunisation
    Katherine King
    Institute for Animal Health Pirbright Laboratory, Pirbright, Woking, Surrey GU24 0NF, UK
    Vaccine 29:4593-600. 2011
    ..Cross-protection was correlated with the ability of different ASFV isolates to stimulate immune lymphocytes from the OURT88/3 and OURT88/1 immunised pigs...
  29. doi Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania
    Muhammad Bakari
    Department of Internal Medicine, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania
    Vaccine 29:8417-28. 2011
    ....
  30. pmc Novel chikungunya vaccine candidate with an IRES-based attenuation and host range alteration mechanism
    Kenneth Plante
    Institute for Human Infections and Immunity, Sealy Center for Vaccine Development, and Department of Pathology, University of Texas Medical Branch, Galveston, Texas, United States of America
    PLoS Pathog 7:e1002142. 2011
    ..Furthermore, it is incapable of replicating in mosquito cells or infecting mosquitoes in vivo. This IRES-based attenuation platform technology may be useful for the predictable attenuation of any alphavirus...
  31. pmc Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus
    Thomas W Geisbert
    Department of Microbiology, National Emerging Infectious Diseases Laboratories Institute, Boston University School of Medicine, Boston, Massachusetts 02118, USA
    J Virol 83:7296-304. 2009
    ..In conclusion, we developed an immunization scheme based on a single-injection vaccine that protects nonhuman primates against lethal challenge with representative strains of all human pathogenic filovirus species...
  32. ncbi Coronavirus avian infectious bronchitis virus
    Dave Cavanagh
    Institute for Animal Health, Compton Laboratory, Compton, Newbury, Berkshire RG20 7NN, United Kingdom
    Vet Res 38:281-97. 2007
    ..Experimental vector IB vaccines and genetically manipulated IBVs--with heterologous spike protein genes--have produced promising results, including in the context of in ovo vaccination...
  33. pmc Vector choice determines immunogenicity and potency of genetic vaccines against Angola Marburg virus in nonhuman primates
    Thomas W Geisbert
    United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland 21702 5011, USA
    J Virol 84:10386-94. 2010
    ....
  34. ncbi Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine
    Sagar U Kapadia
    Department of Pathology, Yale University School of Medicine, New Haven, CT 06510, USA
    Virology 340:174-82. 2005
    ..A VSV-vectored SARS vaccine could have significant advantages over other SARS vaccine candidates described to date...
  35. doi Decreased antibody titers and booster responses in tick-borne encephalitis vaccinees aged 50-90 years
    Birgit Weinberger
    Institute for Biomedical Aging Research, Austrian Academy of Sciences, Rennweg 10, 6020 Innsbruck, Austria
    Vaccine 28:3511-5. 2010
    ..Our results clearly indicate that the responsiveness of the immune system to vaccination is already impaired at the age of 50...
  36. pmc Substitutions in the glycoprotein (GP) of the Candid#1 vaccine strain of Junin virus increase dependence on human transferrin receptor 1 for entry and destabilize the metastable conformation of GP
    Magali E Droniou-Bonzom
    Department of Molecular Microbiology and Immunology, University of Southern California, Keck School of Medicine, 2011 Zonal Avenue, HMR502, Los Angeles, CA 90033, USA
    J Virol 85:13457-62. 2011
    ..Lastly, we identified an increased dependence of Cd1 GP on human transferrin receptor type 1 (hTfR-1) for entry, which may affect the tropism of the attenuated strain in vivo...
  37. pmc Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions
    Christiana Fogg
    Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Virol 78:10230-7. 2004
    ..Three immunizations with the three-protein combination were necessary and sufficient for complete protection. These studies suggest the feasibility of a multiprotein smallpox vaccine...
  38. doi Cell-mediated immune response and cross-protective efficacy of binary ethylenimine-inactivated bluetongue virus serotype-1 vaccine in sheep
    Channakeshava Sokke Umeshappa
    Center for Animal Disease Research and Diagnosis, Pathology Laboratory, Indian Veterinary Research Institute, Izatnagar 243 122, Bareilly, Uttar Pradesh, India
    Vaccine 28:2522-31. 2010
    ..Collectively, these data suggested that inactivated BTV-1 vaccine induced appreciable CMI and greatly reduced the severity of heterologous BTV-23 infection...
  39. ncbi Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C
    Carmen Elena Gómez
    Department of Molecular and Cellular Biology, Centro Nacional de Biotecnologia, CSIC, Ciudad Universitaria Cantoblanco, 28049 Madrid, Spain
    Vaccine 25:1969-92. 2007
    ..These results demonstrate the immunogenic potential of MVA-C and NYVAC-C as novel vaccine candidates against clade C of HIV-1...
  40. ncbi Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18
    Diana V Pastrana
    Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, MD 20892 4263, USA
    Virology 321:205-16. 2004
    ..The SEAP pseudovirus-based neutralization assay should be a practical method for quantifying potentially protective antibody responses in HPV natural history and prophylactic vaccine studies...
  41. pmc Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections
    Dana L Swenson
    U S Army Medical Research Institute of Infectious Diseases, 1425 Porter St, Fort Detrick, Frederick, Maryland 21702 5011, USA
    Clin Vaccine Immunol 15:460-7. 2008
    ..This study indicates the feasibility of vaccination against all current filovirus threats in the event of natural hemorrhagic fever outbreak or biological attack...
  42. ncbi Adenoviruses as vaccine vectors
    Nia Tatsis
    The Wistar Institute, University of Pennsylvania, Philadelphia, PA 19104, USA
    Mol Ther 10:616-29. 2004
    ..This field is growing at an exciting and rapid pace, thus we have limited our scope to the use of adenoviral vectors as vaccines against viral pathogens...
  43. ncbi Studies of genetically defined chimeras of a European type A virus and a South African Territories type 2 virus reveal growth determinants for foot-and-mouth disease virus
    H G van Rensburg
    Onderstepoort Veterinary Institute, Exotic Diseases Division, Private Bag X05, Onderstepoort 0110, South Africa
    J Gen Virol 85:61-8. 2004
    ..Evaluation of the growth of various SAT2/A12 chimeras created during the derivation of SAT2 infectious cDNA suggested incompatibilities between the non-structural proteins of ZIM/7/83 and the 5' UTR of A(12)...
  44. doi EV71: an emerging infectious disease vaccine target in the Far East?
    Juan Xu
    Department of Microbiology and Immunology, Nanjing Medical University, Nanjing 210030, China
    Vaccine 28:3516-21. 2010
    ....
  45. ncbi Effective synthetic peptide vaccine for foot-and-mouth disease in swine
    Chang Yi Wang
    United Biomedical Inc, 25 Davids Drive, Hauppauge, NY 11788, USA
    Vaccine 20:2603-10. 2002
    ..5 microg, and a mild adjuvant that caused no lesions. A safe chemically-defined product would have considerable advantages for vaccination against FMD...
  46. pmc Recombinant viral vaccines expressing merozoite surface protein-1 induce antibody- and T cell-mediated multistage protection against malaria
    Simon J Draper
    The Jenner Institute, University of Oxford, Old Road Campus Research Building, Oxford OX3 7DQ, UK
    Cell Host Microbe 5:95-105. 2009
    ..Multistage immunity against malaria can thus be achieved by using viral vectors recombinant for MSP-1...
  47. pmc Dengue and dengue hemorrhagic fever
    D J Gubler
    Division of Vector Borne Infectious Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado 80522, USA
    Clin Microbiol Rev 11:480-96. 1998
    ..A major challenge for public health officials in all tropical areas of the world is to develop and implement sustainable prevention and control programs that will reverse the trend of emergent dengue hemorrhagic fever...
  48. pmc Rift valley fever vaccines
    Tetsuro Ikegami
    Department of Pathology, The University of Texas Medical Branch, Galveston, TX 77555 0438, USA
    Vaccine 27:D69-72. 2009
    ..Effective vaccination of both humans and ruminants is the best approach to control Rift Valley fever. This article summarizes the development of inactivated RVFV vaccine, live attenuated vaccine, and other new generation vaccines...
  49. doi Evaluation of the efficacy and safety of the Rift Valley Fever Clone 13 vaccine in sheep
    Baptiste Dungu
    Onderstepoort Biological Products Ltd, Private Bag X07, Onderstepoort 0110, South Africa
    Vaccine 28:4581-7. 2010
    ..A vaccine dose-response effect was also observed...
  50. pmc Foot-and-mouth disease
    Marvin J Grubman
    Plum Island Animal Disease Center, USDA, Agricultural Research Service, North Atlantic Area, Greenport, New York 11944, USA
    Clin Microbiol Rev 17:465-93. 2004
    ....
  51. pmc An attenuated strain of enterovirus 71 belonging to genotype a showed a broad spectrum of antigenicity with attenuated neurovirulence in cynomolgus monkeys
    Minetaro Arita
    Department of Virology II, National Institute of Infectious Diseases, 4 7 1 Gakuen, Musashimurayama shi, Tokyo 208 0011, Japan
    J Virol 81:9386-95. 2007
    ..In the CNS, EV71(S1-3') was isolated only from the spinal cord. These results indicate that EV71(S1-3') acts as an effective antigen, although this attenuated strain was still neurotropic when inoculated via the intravenous route...
  52. ncbi Inactivation of the viral interleukin 1beta receptor improves CD8+ T-cell memory responses elicited upon immunization with modified vaccinia virus Ankara
    Caroline Staib
    GSF Institute of Molecular Virology and Institute of Virology, Technical University of Munich, Trogerstrasse 4b, 81675 Munchen, Germany
    J Gen Virol 86:1997-2006. 2005
    ..These data suggest that deletion of the viral IL1betaR gene may be considered a relevant approach to amplify the virus-specific CD8+ memory T-cell response and duration of protective immunity obtained after MVA vaccination...
  53. ncbi Protection of neonatal mice from lethal enterovirus 71 infection by maternal immunization with attenuated Salmonella enterica serovar Typhimurium expressing VP1 of enterovirus 71
    Cheng Hsun Chiu
    Department of Pediatrics, Chang Gung Children s Hospital, Chang Gung University College of Medicine, Kweishan, Taoyuan 333, Taiwan
    Microbes Infect 8:1671-8. 2006
    ..Our data indicated that Salmonella-based VP1 subunit vaccines are a promising vaccine strategy in the prevention of EV71 infection...
  54. ncbi The three-dimensional structure of foot-and-mouth disease virus at 2.9 A resolution
    R Acharya
    Laboratory of Molecular Biophysics, Oxford, UK
    Nature 337:709-16. 1989
    ..The most immunogenic portion of the capsid, which acts as a potent peptide vaccine, forms a disordered protrusion on the virus surface...
  55. doi Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep
    Michael Eschbaumer
    Institute of Diagnostic Virology, Friedrich Loeffler Institut, Südufer 10, 17493 Greifswald Insel Riems, Germany
    Vaccine 27:4169-75. 2009
    ..Only one vaccinated animal was very weakly positive in the real-time RT-PCR at day 10 after challenge infection, and one seronegative sheep in one of the vaccine groups was not protected...
  56. doi Prophylaxis and therapy for Chikungunya virus infection
    Thérèse Couderc
    Groupe Microorganismes et Barrières de l Hôte and Unité Interactions Moléculaires Flavivirus Hôtes, Centre National de Référence des Arbovirus, Institut Pasteur, INSERM, Avenir U604, and Universite Paris Descartes, Hopital Necker Enfants Malades, Paris, France
    J Infect Dis 200:516-23. 2009
    ....
  57. pmc Nipah virus: vaccination and passive protection studies in a hamster model
    V Guillaume
    INSERM Unite 404 UBIVE, Institut Pasteur, CERVI, IFR 128, Lyon, France
    J Virol 78:834-40. 2004
    ....
  58. doi Mucosal immunization of rhesus macaques with Rift Valley Fever MP-12 vaccine
    John C Morrill
    Applied Research Division, US Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland, USA
    J Infect Dis 204:617-25. 2011
    ..A single inoculation of the RVF MP-12 live attenuated vaccine by the aerosol or intranasal route may provide an alternative route of protective immunization to RVFV in addition to conventional intramuscular injection...
  59. doi Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats
    E Breard
    Anses, UMR Virology 1161, Laboratoire de Sante Animale, Maisons Alfort, France
    Vaccine 29:2495-502. 2011
    ..Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines...
  60. pmc Age affects quantity but not quality of antibody responses after vaccination with an inactivated flavivirus vaccine against tick-borne encephalitis
    Karin Stiasny
    Department of Virology, Medical University of Vienna, Vienna, Austria
    PLoS ONE 7:e34145. 2012
    ..Our work indicates that healthy elderly people are able to produce antibodies in response to vaccination with similar avidity and functional activity as young individuals, albeit at lower titers...
  61. pmc Evaluation of Lassa virus vaccine immunogenicity in a CBA/J-ML29 mouse model
    Marco A Goicochea
    Institute of Human Virology, University of Maryland, School of Medicine, Baltimore, MD 21201, United States
    Vaccine 30:1445-52. 2012
    ..The CBA/J-ML29 model can be useful immunological tool for the preliminary evaluation of immunogenicity and efficacy of vaccine candidates against LASV outside of BSL-4 containment facilities...
  62. pmc A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge
    Meagan Bolles
    Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    J Virol 85:12201-15. 2011
    ....
  63. doi Recent advances in the molecular epidemiology and control of human enterovirus 71 infection
    Peter C McMinn
    Infectious Diseases and Immunology, Sydney Medical School, The University of Sydney, NSW 2006, Australia
    Curr Opin Virol 2:199-205. 2012
    ..Furthermore, ongoing investigations into the molecular basis of HEV71 infection and virulence have pointed the way towards novel approaches to live attenuated vaccine development...
  64. ncbi Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses
    Steven M Jones
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, 1015 Arlington Street, Winnipeg, Manitoba R3E 3R2, Canada
    Nat Med 11:786-90. 2005
    ..No evidence of EBOV or MARV replication was detected in any of the protected animals after challenge. Our data suggest that these vaccine candidates are safe and highly efficacious in a relevant animal model...
  65. doi Single dose adenovirus vectored vaccine induces a potent and long-lasting immune response against rabbit hemorrhagic disease virus after parenteral or mucosal administration
    Erlinda Fernández
    Animal Biotechnology Division, Center for Genetic Engineering and Biotechnology, PO Box 6162, CP 10600, Havana, Cuba
    Vet Immunol Immunopathol 142:179-88. 2011
    ..IgA specific antibodies were only found in saliva of rabbits immunized by intranasal instillation. The feasibility of VP60 production and vaccination of rabbits with replication-defective adenoviral vectors was demonstrated...
  66. doi Current status of vaccines against infectious bursal disease
    Hermann Muller
    Institute for Virology, Faculty of Veterinary Medicine, University of Leipzig, An den Tierkliniken 29, Leipzig, Germany
    Avian Pathol 41:133-9. 2012
    ..Recently, live viral vector vaccines have been licensed in several countries and are reaching the market. Here, the current status of IBD vaccines is discussed...
  67. doi High burden of tick-borne encephalitis in Slovenia--challenge for vaccination policy
    Marta Grgic-Vitek
    National Institute of Public Health, Trubarjeva 2, 1000 Ljubljana, Slovenia
    Vaccine 29:5178-83. 2011
    ....
  68. doi FMD subunit vaccine produced using a silkworm-baculovirus expression system: protective efficacy against two type Asia1 isolates in cattle
    Zhiyong Li
    State Key Laboratory of Veterinary Etiological Biology, Lanzhou Veterinary Research Institute, Chinese Academy of Agriculture Sciences, 1 Xujiaping, Lanzhou 730046, China
    Vet Microbiol 149:99-103. 2011
    ..When challenged with two Chinese isolates, the subunit vaccine could achieve 6.5 PD(50) (challenged with Asia I/HNK/CHA/05 strain) and 5.2 PD(50) (challenged with Asia I/JSL/05 strain) per dose...
  69. pmc A multivalent vaccination strategy for the prevention of Old World arenavirus infection in humans
    Jason Botten
    Department of Medicine, University of Vermont College of Medicine, Burlington, VT 05405, USA
    J Virol 84:9947-56. 2010
    ....
  70. doi Evaluation of recombinant E2 protein-based and whole-virus inactivated candidate vaccines against chikungunya virus
    Manish Kumar
    National Institute of Virology, Microbial Containment Complex, Sus Road, Pashan, Pune 411021, India
    Vaccine 30:6142-9. 2012
    ..With the re-emergence of chikungunya virus (CHIKV) in an explosive form and in the absence of a commercially available vaccine, we aimed to develop candidate vaccines employing recombinant E2 protein or chemically inactivated whole virus...
  71. pmc Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever
    Luis M Branco
    Tulane University Health Sciences Center, New Orleans, LA, USA
    Virol J 7:279. 2010
    ..To this end, we have employed efficient mammalian expression systems to generate a Lassa virus (LASV)-like particle (VLP)-based modular vaccine platform...
  72. pmc An intranasally delivered Toll-like receptor 7 agonist elicits robust systemic and mucosal responses to Norwalk virus-like particles
    Lissette S Velasquez
    Center for Infectious Diseases and Vaccinology, Biodesign Institute, Arizona State University, Tempe, AZ 85287 5001, USA
    Clin Vaccine Immunol 17:1850-8. 2010
    ..g., respiratory and reproductive tracts) are desired...
  73. pmc Quantitative trait loci for variation in immune response to a Foot-and-Mouth Disease virus peptide
    Richard J Leach
    The Roslin Institute and Royal Dick School of Veterinary Studies, University of Edinburgh, Roslin Biocentre, Roslin, Midlothian, EH25 9PS, UK
    BMC Genet 11:107. 2010
    ..T cell and antibody (IgG1 and IgG2) responses were measured at several time points post immunisation. All experimental animals (F0, F1 and F2, n = 982) were genotyped with 165 microsatellite markers for the genome scan...
  74. ncbi Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus
    Raymond H See
    University of British Columbia Centre for Disease Control, Vancouver, BC V5Z 4R4, Canada
    J Gen Virol 87:641-50. 2006
    ..Finally, the sera of vaccinated mice contained antibodies to S, further suggesting a role for this protein in conferring protective immunity against SARS-CoV infection...
  75. pmc Effect of preexisting immunity on an adenovirus vaccine vector: in vitro neutralization assays fail to predict inhibition by antiviral antibody in vivo
    Susan L Pichla-Gollon
    Division of Infectious Diseases, The Children s Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    J Virol 83:5567-73. 2009
    ..The results thus suggest that in vitro neutralization assays may not reliably predict the effects of virus-specific antibodies on adenovirus vectors in vivo...
  76. ncbi Safety testing for neurovirulence of novel live, attenuated flavivirus vaccines: infant mice provide an accurate surrogate for the test in monkeys
    Thomas P Monath
    Acambis Inc, 38 Sidney Street, Cambridge, MA 02139, USA
    Biologicals 33:131-44. 2005
    Current requirements for control of live viral vaccines, including yellow fever 17D, produced from potentially neurotropic wild-type viruses include tests for neurovirulence in nonhuman primates...
  77. ncbi Development of synthetic peptide ELISA based on nonstructural protein 2C of foot and mouth disease virus
    Jae Ku Oem
    National Veterinary Research and Quarantine Service, Ministry of Agriculture, Anyang 430 824, Korea
    J Vet Sci 6:317-25. 2005
    ..These results demonstrate that the synthetic 2C peptide ELISA can be a complementary marker to differentiate FMDV-infected from vaccinated on a herd basis...
  78. doi Seroconversion, neutralising antibodies and protection in bluetongue serotype 8 vaccinated sheep
    C A L Oura
    Institute for Animal Health, Pirbright Laboratory, Ash Road, Pirbright, Woking, Surrey GU240NF, UK
    Vaccine 27:7326-30. 2009
    ..The sandwich (double antigen) ELISA assays were found to be more sensitive at detecting antibodies in vaccinated sheep than the competitive ELISAs...
  79. ncbi Immunogenicity of papaya mosaic virus-like particles fused to a hepatitis C virus epitope: evidence for the critical function of multimerization
    Jérôme Denis
    Centre de Recherche en Infectiologie, Pavillon CHUL, Universite Laval, 2705 Boul Laurier, Quebec, PQ, Canada
    Virology 363:59-68. 2007
    ..These results demonstrate for the first time the potential of the PapMV vaccine platform and the critical function of multimerization in its immunogenicity...
  80. ncbi Recombinant capripoxviruses expressing proteins of bluetongue virus: evaluation of immune responses and protection in small ruminants
    Aurélie Perrin
    CIRAD Département BioS, UPR15, TA A 15, Campus International de Baillarguet, 34398 Cedex 5 Montpellier, France
    Vaccine 25:6774-83. 2007
    ..Finally, partial protection of sheep challenged 3 weeks after BTV-Cpox administration with a virulent strain of BTV-2, was observed...
  81. pmc Cross-priming of cytotoxic T cells dictates antigen requisites for modified vaccinia virus Ankara vector vaccines
    Georg Gasteiger
    GSF Institute for Molecular Virology, Schneckenburgerstrasse 8, D 81675 Munich, Germany
    J Virol 81:11925-36. 2007
    ..Our data are essential for improved MVA vaccine design, as they demonstrate the need for optimal adjustment of the target antigen properties to the intrinsic requirements of the delivering vector system...
  82. pmc Seroprevalence of neutralizing antibodies to adenovirus type 5 among children in India: implications for recombinant adenovirus-based vaccines
    Mohan Babu Appaiahgari
    National Institute of Immunology, Aruna saf Ali Marg, JNU Complex, New Delhi 110067, India
    Clin Vaccine Immunol 14:1053-5. 2007
    ..This opens up the scope for the use of recombinant Ad5-based vaccines in this age group...
  83. pmc Complete protection from papillomavirus challenge after a single vaccination with a vesicular stomatitis virus vector expressing high levels of L1 protein
    Anjeanette Roberts
    Department of Pathology Section of Comparative Medicine, Yale University School of Medicine, New Haven, Connecticut 06510
    J Virol 78:3196-9. 2004
    ..We conclude that the level of L1 protein expression is critical in generating complete immunity with a single-dose vaccine...
  84. ncbi Marker vaccine strategies and candidate CSFV marker vaccines
    Xiao Nan Dong
    Laboratory of Immunology, Department of Biology, Tsinghua University, Protein Science Laboratory of the Ministry of Education, Beijing 100084, PR China
    Vaccine 25:205-30. 2007
    ..Here, we summarized current strategies and candidate CSFV marker vaccines. These strategies and methods are also helpful for the development of new-generation vaccines against other diseases...
  85. pmc Multiple innate immune pathways contribute to the immunogenicity of recombinant adenovirus vaccine vectors
    Elizabeth G Rhee
    Division of Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA
    J Virol 85:315-23. 2011
    ..Stimulation of multiple innate immune mechanisms may prove a generalizable property of potent vaccines, and this strategy could be harnessed in the development of next-generation vaccine vectors and adjuvants...
  86. pmc Postexposure treatment of Marburg virus infection
    Thomas W Geisbert
    National Emerging Infectious Diseases Laboratories Institute, Boston, Massachusetts 02118, USA
    Emerg Infect Dis 16:1119-22. 2010
    ..We protected 5/6 monkeys when this vaccine was given 24 h after challenge; 2/6 animals were protected when the vaccine was administered 48 h postinfection...
  87. pmc Immunization of cattle with recombinant Newcastle disease virus expressing bovine herpesvirus-1 (BHV-1) glycoprotein D induces mucosal and serum antibody responses and provides partial protection against BHV-1
    Sunil K Khattar
    Virginia Maryland Regional College of Veterinary Medicine, University of Maryland, 8075 Greenmead Drive, College Park, MD 20742, USA
    Vaccine 28:3159-70. 2010
    ....
  88. doi Efficacy of a modified live porcine reproductive and respiratory syndrome virus (PRRSV) vaccine in pigs naturally exposed to a heterologous European (Italian cluster) field strain: Clinical protection and cell-mediated immunity
    Paolo Martelli
    Department of Animal Health, University of Parma, Via del Taglio, 10, 43126 Parma, Italy
    Vaccine 27:3788-99. 2009
    ....
  89. pmc In vivo evaluation of the cross-genotype neutralizing activity of polyclonal antibodies against hepatitis C virus
    Philip Meuleman
    Center for Vaccinology, Ghent University and Hospital, Ghent, Belgium
    Hepatology 53:755-62. 2011
    ..Animals in which the antibody pretreatment failed displayed a clear delay in the kinetics of viral infection. Sequence analysis of the recovered viruses did not suggest antibody-induced viral escape...
  90. ncbi Immune responses of pigs inoculated with a recombinant fowlpox virus coexpressing GP5/GP3 of porcine reproductive and respiratory syndrome virus and swine IL-18
    Guoshun Shen
    Genetic Engineering Laboratory, Academy of Military Medical Sciences, Changchun 130062, PR China
    Vaccine 25:4193-202. 2007
    ..The results demonstrated the potential use of a fowlpox virus-based recombinant vaccine in the control and prevention of PRRSV infections...
  91. ncbi Differential effects of the type I interferons alpha4, beta, and epsilon on antiviral activity and vaccine efficacy
    Stephanie L Day
    Division of Immunology and Genetics, John Curtin School of Medical Research, Australian National University, Canberra, Australian Capital Territory, Australia
    J Immunol 180:7158-66. 2008
    ..Our data also indicate that while IFN-epsilon exhibits certain biological traits similar to other type I IFNs, it may also have a specific role in mucosal immune regulation that is quite distinct...
  92. doi Protection against lethal Rift Valley fever virus (RVFV) infection in transgenic IFNAR(-/-) mice induced by different DNA vaccination regimens
    Gema Lorenzo
    Centro de Investigación en Sanidad Animal CISA INIA, Ctra Algete El Casar, 28130 Valdeolmos, Madrid, Spain
    Vaccine 28:2937-44. 2010
    ..Interestingly, the combination of both vaccine constructs induced specific lymphoblast proliferation upon stimulation with a recombinant nucleoprotein...
  93. doi Synthesis of empty capsid-like particles of Asia I foot-and-mouth disease virus in insect cells and their immunogenicity in guinea pigs
    Yimei Cao
    Lanzhou Veterinary Research Institute of Chinese Academy of Agriculture Science, State Key Laboratory of Veterinary Etiological Biology, National Foot and mouth Disease Reference Laboratory, Yanchangpu, Lanzhou, Gansu, The People s Republic of China
    Vet Microbiol 137:10-7. 2009
    ..These recombinant, non-infectious, FMDV empty capsids are potentially useful for the development of new diagnostic techniques and vaccines...
  94. doi Interleukin-15 enhance DNA vaccine elicited mucosal and systemic immunity against foot and mouth disease virus
    Xiao Wang
    State Key Laboratory for Agro Biotechnology, College of Biological Science, China Agricultural University, Beijing 100094, China
    Vaccine 26:5135-44. 2008
    ..Taken together, the results demonstrated that intranasal delivery of IL-15 as a mucosal adjuvant can enhance the antigen-specific mucosal and systemic immune responses, which may provide a protection against the FMDV initial infection...
  95. pmc Current status of veterinary vaccines
    Els N T Meeusen
    Animal Biotechnology Research Laboratories, Department of Physiology, Building 13F, Monash University, Clayton, Victoria 3800, Australia
    Clin Microbiol Rev 20:489-510, table of contents. 2007
    ..The continued interaction between animals and human researchers and health professionals will be of major importance for adapting new technologies, providing animal models of disease, and confronting new and emerging infectious diseases...
  96. ncbi Protective immune response of the capsid precursor polypeptide (P1) of foot and mouth disease virus type 'O' produced in Pichia pastoris
    V Balamurugan
    Molecular Virology Laboratory, Indian Veterinary Research Institute, Hebbal, Bangalore 560 024, India
    Virus Res 92:141-9. 2003
    ..This is the first report on the production of FMDV structural proteins in yeast and their application as a vaccine...
  97. pmc Priming with secreted glycoprotein G of respiratory syncytial virus (RSV) augments interleukin-5 production and tissue eosinophilia after RSV challenge
    T R Johnson
    Department of Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232 2582, USA
    J Virol 72:2871-80. 1998
    ..The ability of RSV to secrete G protein may therefore represent a viral strategy for immunomodulation and be a key determinant of disease pathogenesis...
  98. ncbi Severe acute respiratory syndrome vaccine development: experiences of vaccination against avian infectious bronchitis coronavirus
    Dave Cavanagh
    Institute for Animal Health, Division of Molecular Biology, Compton Laboratory, Newbury, Berkshire, UK
    Avian Pathol 32:567-82. 2003
    ....
  99. ncbi Vaccines against bluetongue in Europe
    Giovanni Savini
    OIE Reference Laboratory for Bluetongue, Istituto Zooprofilattico Sperimentale dell Abruzzo e del Molise G Caporale, Teramo, Italy
    Comp Immunol Microbiol Infect Dis 31:101-20. 2008
    ..Additional BTV inactivated vaccines are currently under development, as well as new generation vaccines including recombinant vaccines...
  100. ncbi Expression of the major core structural protein (VP7) of bluetongue virus, by a recombinant capripox virus, provides partial protection of sheep against a virulent heterotypic bluetongue virus challenge
    A M Wade-Evans
    Institute for Animal Health, Pirbright Laboratory, Woking, Surrey, United Kingdom
    Virology 220:227-31. 1996
    ....
  101. pmc Structural insights into the mechanisms of antibody-mediated neutralization of flavivirus infection: implications for vaccine development
    Theodore C Pierson
    Viral Pathogenesis Section, Laboratory of Viral Diseases, National Institutes of Health, 33 North Drive, Building 33, Room 1E19A 2, Bethesda, MD 20892, USA
    Cell Host Microbe 4:229-38. 2008
    ..These insights have identified factors that govern the potency of neutralizing antibodies and will inform the design and evaluation of novel vaccines...

Research Grants85

  1. PATHOGENIC CONVERSION OF ATTENUATED SIV VACCINES
    Earl Sawai; Fiscal Year: 2003
    ..well as replication-competent SIV vectors expressing cytokines in place of nef, were tested as live-attenuated viral vaccines in juveniles and adults...
  2. Molecular Basis of Flavivirus Neurovirulence
    William Wold; Fiscal Year: 2007
    ..Information from these studies may be used to design and improve live-attenuated viral vaccines for viruses of public health importance, as well as to gain insight into the mechanisms of viral pathogenesis...
  3. The Immunogenetics of Measles Immunity
    Gregory A Poland; Fiscal Year: 2010
    ..Our broad objective is to determine the genetic mechanisms influencing the immune response to live viral vaccines and to answer the question of how and to what degree heterogeneity in immune responses depends upon ..
  4. The Immunogenetics of Measles Immunity
    Gregory Poland; Fiscal Year: 2009
    ..Our broad objective is to determine the genetic mechanisms influencing the immune response to live viral vaccines and to answer the question of how and to what degree heterogeneity in immune responses depends upon ..
  5. IMMUNOGENETIC MECHANISMS OF VACCINE RESPONSE
    Gregory Poland; Fiscal Year: 2005
    ..genetic mechanisms that influence the immune response (antibody level and lymphoproliferative responses) to viral vaccines. We propose to study the influence of HLA class I and II genes on the immune response to an established live ..
  6. CHILDHOOD VACCINES AND DENTAL CARIES IMMUNITY
    Daniel Smith; Fiscal Year: 2007
    ..capsular polysaccharide of Haemophilus influenza b), cellular (Bordetella pertussis), or intact attenuated viral vaccines (poliovirus) administered immediately prior to the critical period of mutans streptococcal infectivity; (2) ..
  7. Microcarrier / CEF / Media SYSTEM to make Viral Vaccines
    WILLIAM HILLEGAS; Fiscal Year: 2002
    ..PROPOSED COMMERCIAL APPLICATION: Many animal vital vaccines (e.g. Marek's) and human viral vaccines are produced using chick embryo cells, either in roller bottle systems or in embryonated chicken eggs...
  8. Molecular Basis of Flavivirus Neurovirulence
    Ilya Frolov; Fiscal Year: 2003
    ..Information from these studies may be used to design and improve live-attenuated viral vaccines for viruses of public health importance, as well as to gain insight into the mechanisms of viral pathogenesis...
  9. The Immunogenetics of Measles Immunity
    Gregory Poland; Fiscal Year: 2006
    ..is to determine the genetic mechanisms that influence the immune response (humoral and cell-mediated) to viral vaccines. In this continuation, we focus on the influence of class I and II HLA genes on measures of the cellular ..
  10. HIV Vaccine Design and Development Team
    PAUL MADDON; Fiscal Year: 2001
    ..antiviral antibody response, we will also examine cellular immune response elicited by both the subunit and viral vaccines to guide our selection of the optimum construct(s) for further development...
  11. IMMUNOGENETIC MECHANISMS OF VACCINE RESPONSE
    Gregory A Poland; Fiscal Year: 2010
    ..Our long-term objective isto determine the genetic mechanisms influencing the immune response to live viral vaccines, and to answer the question of how and to what degree differences in immune responses that depend upon the ..
  12. IMMUNOGENETIC MECHANISMS OF VACCINE RESPONSE
    Gregory Poland; Fiscal Year: 2007
    ..Our long-term objective is to determine the genetic mechanisms influencing the immune response to live viral vaccines and to answer the question of how and to what degree differences in immune responses that depends upon the ..
  13. Adjuvant Enhanced Antiviral Immunity
    Jeff Fairman; Fiscal Year: 2007
    ..is the completion of pre-clinical evaluation and development of the CLDC product for use as an adjuvant in viral vaccines and specifically for influenza...
  14. Towards a Vaccine for the Common Cold
    Thomas Smith; Fiscal Year: 2009
    Traditional viral vaccines are normally developed by either creating attenuated viral strains for inoculation, such as the Sabine strain of poliovirus, or by injecting the patients with purified viral proteins such as employed in the ..
  15. Towards a Vaccine for the Common Cold
    THOMAS JAMES SMITH; Fiscal Year: 2010
    Traditional viral vaccines are normally developed by either creating attenuated viral strains for inoculation, such as the Sabine strain of poliovirus, or by injecting the patients with purified viral proteins such as employed in the ..
  16. Burden of RSV and Influenza Virus in Children in Pakistan
    Syed Ali; Fiscal Year: 2009
    ..If a significant burden is confirmed, then a study to use viral vaccines to reduce this burden can be proposed to other funding agencies...
  17. Induction of mucosal SIV immunity in non human primates by secreted Hsp-Gp96
    Eckhard Podack; Fiscal Year: 2007
    ..Anti viral vaccines stimulating cellular immunity have to imitate this process...
  18. Viruses with Pseudolethal Mutations as Vaccines
    Vladimir Yamshchikov; Fiscal Year: 2004
    We propose a new category of viral vaccines consisting of replication competent viruses with pseudolethal mutations that render them incapable to form the infectious progeny...
  19. Analysis of MHC Class Ib-Restricted Polyoma Virus-Specific CD8 T Cells
    ARON LUKACHER; Fiscal Year: 2010
    ..and, given the limited polymorphism of MHC class Ib molecules, provide a platform for developing peptide-based viral vaccines having broad coverage across MHC haplotypes...
  20. Analysis of MHC Class Ib-Restricted Polyoma Virus-Specific CD8 T Cells
    ARON LUKACHER; Fiscal Year: 2009
    ..and, given the limited polymorphism of MHC class Ib molecules, provide a platform for developing peptide-based viral vaccines having broad coverage across MHC haplotypes...
  21. SIV delta vif DNA Vaccines with Cytokine Adjuvants
    Ellen Sparger; Fiscal Year: 2004
    ..In a novel approach to immunization with live-attenuated viral vaccines, cats were inoculated by the intramuscular route with plasmid DNA containing the FIV-delta vif proviral genome...
  22. HIGHLY ATTENUATED SIV VIF DNA VACCINES
    Ellen Sparger; Fiscal Year: 2001
    ..In a novel approach to immunization with live attenuated viral vaccines; cats were inoculated by the intramuscular route with plasmid DNA containing the FIV-delta vif proviral genome...
  23. The influence of host barriers on viral quasispecies diversity and pathogenesis
    Julie K Pfeiffer; Fiscal Year: 2010
    ..this virulence threshold likely will be important for establishing the rational design of many live-attenuated viral vaccines. PUBLIC HEALTH RELEVANCE: RNA viruses such as poliovirus have incredible genome diversity, which complicates ..